文献速递头颈部肿瘤放疗姑息放疗与转移瘤

立体定向体部放疗联合帕博利珠单抗治疗PD-1抑制剂难治性复发或转移性头颈部鳞癌的2期试验

Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-01-09

B组3个月无进展生存率为67%,A组为17%;B组客观缓解率25%,A组无客观缓解。联合治疗安全可行,全面SBRT可能带来获益。

要点

  • B组3个月PFS率67%,A组17%,提示照射全部病灶可能更优。
  • B组客观缓解率25%,A组无客观缓解。
  • B组再照射背景下出现2例(17%)4级毒性。

核心结论

  • 在抗PD-1难治性复发或转移性头颈部鳞癌中,SBRT联合帕博利珠单抗安全可行,照射全部进展病灶时显示出活性。
  • 免疫分析提示基线记忆T细胞和B细胞表型可能与治疗获益相关。

研究设计与样本

  • 前瞻性非随机2期试验,纳入PD-1抑制剂难治性复发或转移性头颈部鳞癌患者。
  • A组单病灶SBRT(6例),B组全部已知寡转移病灶SBRT(12例),均每3周给帕博利珠单抗。
  • 主要终点为3个月无进展生存率,另对外周血单个核细胞行质谱流式和TCRβ测序分析。

主要发现

  • A组中位PFS 1.8个月,B组5.7个月。
  • 3个月PFS率A组17%(1/6),B组67%(8/12)。
  • B组客观缓解率25%(3/12),A组无客观缓解。
  • 中位总生存A组7.6个月(95% CI 0.7-32.9),B组10.1个月(95% CI 5.8-49.7)。
  • B组再照射背景下出现2例(2/12,17%)4级毒性。

关键数值与推荐

  • 主要终点3个月PFS率:A组17%(1/6),B组67%(8/12)。
  • B组客观缓解率25%(3/12),A组无客观缓解。
  • PFS>3个月者基线CD8+中央记忆T细胞频率更高,记忆B细胞CXCR5表达升高。

临床怎么用

  • 对PD-1抑制剂难治性复发或转移性头颈部鳞癌,可考虑全面SBRT联合帕博利珠单抗。
  • 再照射时需警惕4级毒性,本试验B组发生2例(17%)。

局限性

  • A组仅6例,组间比较受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety, feasibility, and clinical efficacy of stereotactic body radiation therapy (SBRT) combined with pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma who progressed on prior PD-1 inhibitor therapy. METHODS AND MATERIALS: This prospective, nonrandomized phase 2 trial enrolled patients with PD-1 inhibitor-refractory R/M head and neck squamous cell carcinoma. In cohort A, a single lesion was treated with SBRT, whereas other sites were left unirradiated. In cohort B, all known oligometastatic lesions were treated with SBRT. Pembrolizumab was administered every 3 weeks in both cohorts. The primary endpoint was 3-month progression-free survival (PFS). Correlative immune analyses were performed on peripheral blood mononuclear cells using mass cytometry and TCRβ sequencing. RESULTS: Eighteen patients were treated (6 in cohort A and 12 in cohort B). The median PFS was 1.8 months in cohort A and 5.7 months in cohort B. The 3-month PFS rate was 17% (1/6) in cohort A and 67% (8/12) in cohort B, with an overall response rate of 25% (3/12) in cohort B and no objective responses in cohort A. Median overall survival was 7.6 months (95% CI, 0.7-32.9) in cohort A and 10.1 months (95% CI, 5.8-49.7) in cohort B. In cohort B, there were 2 (2/12, 17%) grade 4 toxicities observed in the setting of re-irradiation. Correlative studies showed that patients with PFS >3 months had higher baseline frequencies of CD8+ central-memory T cells and elevated CXCR5 expression on memory B cells. CONCLUSIONS: In anti-PD-1-refractory R/M head and neck squamous cell carcinoma, SBRT with pembrolizumab was safe and feasible, suggesting activity when all progressing lesions were treated. Immune profiling describes pre-existing memory T- and B-cell phenotypes that appear to correlate with treatment benefit. These findings support further study and clinical use of comprehensive SBRT plus PD-1 blockade in this hard-to-treat population.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. So J, Droznin AD, Tiwari P, et al. Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 41520892. doi:10.1016/j.ijrobp.2025.12.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。